BioPlus Acquisition Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOSW research report →
Price Chart
About the company
BioPlus Acquisition Corp. was established with the core objective of entering into a business combination, which may take various forms including a merger, share exchange, asset acquisition, stock purchase, or corporate reorganization, with one or more entities. The firm intends to concentrate its search for suitable partners exclusively within the life sciences industry.
- CEO
- Jonathan M. N. Rigby MBA
- IPO
- 2022
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on BIOSW
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $209.07M
- P/E
- 1255.23
- PEG
- 0.08
- P/S
- 0.00
- P/B
- 28.94
- EV/EBITDA
- -182.69
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 2.33%
- ROIC
- -0.49%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,171,000+0.0%
- Op Income
- $-1,171,000
- Net Income
- $5.16M+3375823.3%
- EPS
- $0.20+138.7%
- OCF Growth
- -81798.5%
- FCF Growth
- -81798.5%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.00
- RSI (14)
- 18
- Avg Volume
- 0
No earnings-call transcripts are available for BIOSW yet.
- Free Float
- 0.0%
- Shares Outstanding
- 149.34B
- Float Shares
- 0
of shares held by institutions
48 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Davidson Kempner Partners | 250.00K | ▲ 250.00K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 23 | BioPlus Sponsor LLC | other | 5,749,999 |
| Jun 5, 23 | BioPlus Sponsor LLC | other | 5,749,999 |
| Dec 7, 21 | BioPlus Sponsor LLC | other | 380,000 |
| Dec 7, 21 | BioPlus Sponsor LLC | other | 0 |
| Dec 2, 21 | BioPlus Sponsor LLC | other | 5,175,000 |
| Dec 2, 21 | Giovannetti Glen | other | 0 |
| Dec 2, 21 | SHERWIN STEPHEN A | other | 0 |
| Dec 2, 21 | LANGE LOUIS G | other | 0 |
| Dec 2, 21 | Cross Shawn | other | 0 |
| Dec 2, 21 | Eastman Ronald W | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BIOSW coverage
Recent articles, reports, and earnings notes.
No research on BIOSW yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIOSW report →